Sirolimus in liver transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Sirolimus, an mTOR inhibitor, is increasingly adopted in liver transplantation since 1999.
• It exhibits distinct immunosuppressive, antifibrotic, and antineoplastic properties compared to calcineurin inhibitors.
• Its unique side-effect profile presents potential advantages over traditional immunosuppressants.

Purpose of the Study:

• To review the published data on sirolimus use in liver transplantation.
• To focus on the advantages and disadvantages of sirolimus in this patient population.
• To discuss the antifibrotic and antineoplastic benefits of sirolimus in liver transplant recipients.

Main Methods:

• Literature review of published data on sirolimus in liver transplantation.
• Analysis of clinical side-effect profiles.
• Evaluation of biologic effects including immunosuppression, antifibrosis, and antineoplasia.

Main Results:

• Sirolimus inhibits lymphocyte proliferation, fibrosis, and fibroblast proliferation.
• Unlike calcineurin inhibitors, it does not typically cause glucose intolerance, hypertension, or renal insufficiency.
• Potential adverse effects include hyperlipidemia and hepatic artery thrombosis in liver transplant recipients.

Conclusions:

• Sirolimus presents significant potential advantages over conventional immunosuppressive agents in liver transplantation.
• Its antifibrotic and antineoplastic effects warrant further investigation for patient benefit.
• Careful consideration of its distinct side-effect profile is crucial for optimal patient management.